Decoction for treating helicobacter pylori-associated gastritis

Abstract

The invention relates to the field of a traditional Chinese medicine formula, in particular to a decoction for treating helicobacter pylori-associated gastritis, which is prepared by taking coptis, processed rhizoma pinelliae, radix scutellariae, dandelion, fingered citron, lotus leaf, cortex magnoliae officinalis, fried bighead atractylodes rhizome and licorice as raw materials. The raw materials are added into water for soaking, then the raw materials are decocted, and residues are removed to obtain a filtered solution. The decoction is characterized by being prepared from the following rawmaterials in concrete percentage by weight: 4-6% of coptis, 7-9% of processed rhizoma pinelliae, 8-10% of radix scutellariae, 12-25% of dandelion, 12-16% of fingered citron, 10-14% of lotus leaf, 10-12% of cortex magnoliae officinalis, 12-22% of fried bighead atractylodes rhizome and 6-8% of licorice. The decoction provided by the invention has low raw material cost and good compliance, does not have toxic side effects, can achieve the purposes of resisting bacteria, diminishing inflammation, enhancing protection factors and regulating the immune function of an antibody, and can be used for effectively treating helicobacter pylori-associated gastritis.

Description

technical field [0001] The invention relates to a Chinese patent medicine preparation, in particular to a decoction for treating gastritis associated with Helicobacter pylori. Background technique [0002] As we all know, Helicobacter pylori is a microaerophilic Gram-negative bacillus, and the infection rate of the global population is as high as 50%. The four diseases of tissue lymphoma are closely related, and it is considered that the eradication of Helicobacter pylori is extremely important for the treatment of the above four diseases. Helicobacter pylori infection is an important cause of the occurrence and recurrence of chronic active gastritis and peptic ulcer. The treatment of Helicobacter pylori infection has always been the focus and hotspot in the field of Helicobacter pylori research. The eradication of Helicobacter pylori in modern medicine mainly uses a proton pump inhibitor or a colloid secretory plus clarithromycin, amoxicillin or tetracycline, metronidazol...

AI Technical Summary

Problems solved by technology

However, with the increase of resistant strains of H. pylori, the eradication rate of H. pylori with standard 7- or 10-day triple therapy has gradually declined, and in some areas has dropped below 80%.

At the same time, the occurrence of western medicine resistance, the occurrence of drug toxicity and adverse reactions increased significantly, and the recurrence rate of the disease was high

Images